Clinical Trials Logo

Filter by:
NCT ID: NCT04833413 Recruiting - Insulin Clinical Trials

Regimen Switch After Intensive Insulin Therapy

Start date: April 15, 2021
Phase:
Study type: Observational

Insulin intensive therapy have traditionally been considered a sequential therapy in type 2 diabetes last choice, a number of guidelines and consensus recommendations insulin intensive therapy can be as obvious hyperglycemia in patients with newly diagnosed T2DM part of a line, a subset of patients after insulin intensive treatment target often need to change to other treatments, especially for senile diabetes patients, due to its self management ability, simplify the insulin solution is more urgent. Current clinical guidelines do not provide specific clinical guidance, such as the timing and method of switch after initial insulin intensive therapy. The purpose of this study was to explore the timing, suitable population and conversion methods of insulin regimens after treatment.

NCT ID: NCT04833374 Recruiting - IgA Nephropathy Clinical Trials

Steroids Therapy in IgA Nephropathy With Crescents

Start date: May 24, 2021
Phase: Phase 3
Study type: Interventional

This prospective, randomized, controlled, multi-center clinical trial will evaluate the effect and security of steroids therapy for patients of IgA nephropathy with crescents.

NCT ID: NCT04833257 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC

Start date: April 14, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the efficacy and safety of a combination of GP chemotherapy and tislelizumab in neoadjuvant therapy of locoregionally advanced nasopharyngeal carcinoma patients.

NCT ID: NCT04833205 Recruiting - Lung Cancer Clinical Trials

Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer

Start date: April 19, 2021
Phase: Phase 2
Study type: Interventional

Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer.

NCT ID: NCT04833192 Recruiting - Clinical trials for Adrenal Incidentaloma

Evaluation of New Diagnostic Indicator of Subclinical Hypercortisolism

Start date: April 1, 2020
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to evaluate the serum dehydroepiandrosterone sulfate in subclinical hypercortisolism

NCT ID: NCT04833036 Recruiting - Colorectal Cancer Clinical Trials

c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI

Start date: October 1, 2019
Phase: Phase 2
Study type: Interventional

The primary endpoint is to evaluate the progression-free survival (PFS).

NCT ID: NCT04832776 Recruiting - Clinical trials for Liver Metastasis Colon Cancer

FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases

Start date: April 17, 2021
Phase: Phase 2
Study type: Interventional

To compare the efficacy of FOLFOXIRI plus Cetuximab and FOLFOXIRI plus Bevacuzumab in the conversion therapy of right-sided colon cancer liver metastases

NCT ID: NCT04832568 Recruiting - Delirium Clinical Trials

Perioperative EEG-Monitoring and Postoperative Delirium in Patients Undergoing Cardiovascular Surgery

Start date: June 17, 2021
Phase:
Study type: Observational

Postoperative delirium is common in patients undergoing cardiovascular surgery and associated with poor outcomes. However the pathogenesis of postoperative delirium is poorly understood. Multichannel electroencephalogram is a recognized tool for identifying neurophysiologic states during anesthesia, sleep, and arousal. The aim of the current study is to evaluate the mechanisms and predictors of postoperative delirium in patients undergoing cardiovascular surgery using electroencephalogram.

NCT ID: NCT04832204 Recruiting - Solid Tumor Clinical Trials

Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases

Start date: March 25, 2021
Phase: Phase 2
Study type: Interventional

Apatinib and SHR-1210 are new drugs produced by jiangsu hengrui pharmaceutical co., LTD. Both are listed in China. The investigators want to design a trial to explore the efficacy and safety of Apatinib and SHR-1210 in patients with solid tumors with only liver metastasis (as second-line treatment). The main purpose is to evaluate the disease progression-free survival (PFS) of Apatinib and SHR-1210 in patients with solid tumors with only liver metastasis (progress after first-line treatment). The secondary purpose is to compare the total survival period (OS); 1-year survival rate, 2-year survival rate; evaluation of drug safety; exploration of related biomarkers in specific subgroups to predict effectiveness or adverse reactions.

NCT ID: NCT04831658 Recruiting - Clinical trials for Primary Central Nervous System Lymphoma

A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma

Start date: March 29, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

To observe the efficacy and safety of a new generation of BTK inhibitor Orelabrutinib combined with PD-1 and fotemustine in the treatment of patients with primary central nervous system lymphoma (PCNSL).